RecombinantRabMAb

Recombinant Anti-TAF9 antibody [EPR12075(B)] (ab169784)

Submit a review Submit a question References (1)
Western blot - Anti-TAF9 antibody [EPR12075(B)] (ab169784)
  • Immunocytochemistry/ Immunofluorescence - Anti-TAF9 antibody [EPR12075(B)] (ab169784)
  • Immunocytochemistry/ Immunofluorescence - Anti-TAF9 antibody [EPR12075(B)] (ab169784)
  • Anti-TAF9 antibody [EPR12075(B)] (ab169784)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR12075(B)] to TAF9
  • Suitable for: WB, ICC/IF
  • Reacts with: Mouse, Rat, Human

Overview

  • Product name

    Anti-TAF9 antibody [EPR12075(B)]
    See all TAF9 primary antibodies

  • Description

    Rabbit monoclonal [EPR12075(B)] to TAF9

  • Host species

    Rabbit

  • Tested applications

    Suitable for: WB, ICC/IFmore details
    Unsuitable for: Flow Cyt,IHC-P or IP

  • Species reactivity

    Reacts with: Mouse, Rat, Human
    Predicted to work with: Cow, Orangutan

  • Immunogen

    Synthetic peptide corresponding to residues in Human TAF9, (Uniprot ID: Q16594)

  • Positive control

    • HeLa, A431, MCF-7 and K562 cell lysates.

  • General notes

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

    Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.

    Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.

    We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.

    In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.

    We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.

    Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.

    Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.

Properties

Applications

Our Abpromise guarantee covers the use of ab169784 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Predicted molecular weight: 29 kDa.
ICC/IF 1/500.

For unpurified use at 1/100 - 1/250
  • Application notes
    Is unsuitable for Flow Cyt,IHC-P or IP.

    • Target

    • Relevance

      TAF9 functions as a component of the DNA-binding general transcription factor complex TFIID and the regulatory transcription complex SAGA. Binding of TFIID to a promoter (with or without TATA element) is the initial step in pre-initiation complex (PIC) formation. TFIID plays a key role in the regulation of gene expression by RNA polymerase II through different activities such as transcription activator interaction, core promoter recognition and selectivity, TFIIA and TFIIB interaction, chromatin modification (histone acetylation by TAF1), facilitation of DNA opening and initiation of transcription. SAGA influences RNA polymerase II transcriptional activity through different activities such as TBP interaction (SPT3 and SPT8) and promoter selectivity, interaction with transcription activators (GCN5, ADA2, ADA3, and TRA1), and chromatin modification through histone acetylation (GCN5).

    • Cellular localization

      Nuclear

    • Database links

      see all

    • Alternative names

      • TAF9 RNA polymerase II, TATA box-binding protein-associated factor, 32kDa antibody
      • MGC:1603 antibody
      • MGC:3647 antibody
      • MGC:5067 antibody
      • RNA polymerase II TBP-associated factor subunit G antibody
      • STAF31/32 antibody
      • TAF17 antibody
      • TAF2G antibody
      • TAF9 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 32kDa antibody
      • TAFII31 antibody
      • TAFII32 antibody
      • TAFIID32 antibody
      • TATA box-binding protein-associated factor 2G antibody
      • TBP associated factor 17 kDa antibody
      • TBP associated factor 9 antibody
      • TBP associated factor, RNA polymerase II, 32-KD antibody
      • transcription initiation factor TFIID 31 kD subunit antibody
      • transcription initiation factor TFIID 31 kDa subunit antibody
      • transcription initiation factor TFIID 32 kDa subunit antibody
      • Transcription initiation factor TFIID subunit 9 antibody
      see all

    Images

    • Western blot - Anti-TAF9 antibody [EPR12075(B)] (ab169784)
      Western blot - Anti-TAF9 antibody [EPR12075(B)] (ab169784)
      All lanes : Anti-TAF9 antibody [EPR12075(B)] (ab169784) at 1/1000 dilution

      Lane 1 : HeLa cell lysate
      Lane 2 : A431 cell lysate
      Lane 3 : MCF7 cell lysate
      Lane 4 : K562 cell lysate

      Lysates/proteins at 10 µg per lane.

      Secondary
      All lanes : Goat anti-rabbit HRP at 1/2000 dilution

      Predicted band size: 29 kDa

    • Immunocytochemistry/ Immunofluorescence - Anti-TAF9 antibody [EPR12075(B)] (ab169784)
      Immunocytochemistry/ Immunofluorescence - Anti-TAF9 antibody [EPR12075(B)] (ab169784)

      Immunocytochemistry/Immunofluorescence analysis of MCF-7 (human breast carcinoma) cells labelling TAF9 with purified ab169784 at 1/500. Cells were fixed with 4% Paraformaldehyde. An Alexa Fluor® 488-conjugated goat anti-rabbit IgG (ab150077) at 1/1000 dilution was used as the secondary antibody. Nuclei couterstained with DAPI (blue).

      Secondary Only Control: PBS was used instead of the primary antibody as the negative control.

    • Immunocytochemistry/ Immunofluorescence - Anti-TAF9 antibody [EPR12075(B)] (ab169784)
      Immunocytochemistry/ Immunofluorescence - Anti-TAF9 antibody [EPR12075(B)] (ab169784)
      Immunofluorescence analysis of MCF7 cells, labeling TAF9 using ab169784 at a 1/100 dilution.
    • Anti-TAF9 antibody [EPR12075(B)] (ab169784)
      Anti-TAF9 antibody [EPR12075(B)] (ab169784)

    References (1)

    Publishing research using ab169784? Please let us know so that we can cite the reference in this datasheet.

    ab169784 has been referenced in 1 publication.

    • Zeng P  et al. Cancer-testis antigen HCA587/MAGEC2 interacts with the general transcription coactivator TAF9 in cancer cells. Mol Med Rep 17:3226-3231 (2018). PubMed: 29257297

    Customer reviews and Q&As

    Show All Reviews Q&A
    Submit a review Submit a question

    There are currently no Customer reviews or Questions for ab169784.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com